 The study found that mutations in COVID-19 patients treated with monoclonal antibodies can reduce or eliminate their ability to neutralize the virus. These mutations were caused by immunovasion mechanisms and could potentially lead to the development of drug-resistant strains. This article was authored by Menorne Ragonette Cronin, Rung Ti-Wen Nutali, Jian Donghua, and others.